Warning: members of the public are being contacted by people claiming to work for AXA Investment Managers UK Limited.  Find out more information and what to do by clicking here.

Why invest in biotech?

Biotechnology is a burgeoning specialist field that is transforming the way diseases are treated. Very loosely, biotechnology is the use of living organisms and molecular biology to produce products, typically in the healthcare sector. It is the innovation engine of the biopharma/drugs sector, often sitting at the cutting edge of the next medical breakthrough.

In the early 2000s the sector was very much in its infancy, but since then it has become crucial to the global healthcare industry. It has a lower correlation to world equities than healthcare and therefore offers diversification benefits alongside a healthcare fund.

In investment terms, biotechnology is:

  • High growth potential
  • Defensive, commercial businesses
  • Innovation-led
  • Built on strong long-term fundamentals supported by structural shifts in demographics and lifestyles


Sitting at the cutting edge of the next medical breakthrough


Acquired by traditional pharma to harness technological innovation


All the top 10 selling drugs globally in 2021 are biotechnology derived


Universe depth increased markedly over the past decade


The AXA Framlington Biotech Fund

The AXA Framlington Biotech Fund invests in shares of listed companies, principally in the biotechnology, genomic and medical research industry. It can invest in companies of any size, based anywhere in the world, although the portfolio tends to be biased towards the US where most biotechnology companies are based.

View funds

Who is AXA Framlington Biotech Fund for?


Investors that see the opportunity in a cutting edge, disruptive technology, with a foundation of commercial companies.


Investors looking to diversify healthcare exposure in a burgeoning technological field with growth characteristics.


Global investors seeking to benefit from demographic factors that are driving growth in the sector.

Why invest in biotech with AXA IM?

AXA IM has a long history of successfully running dedicated healthcare franchises. The AXA Framlington Biotech Fund was established in 2001 and has delivered continued long-term outperformance versus the benchmark. You can view the performance history here. 

The managers bring a wealth of dedicated healthcare and biotech experience having a collective 33 years covering the sector. They sit within the broader global equities team that spans London, China, Singapore, Hong Kong and Paris. This presents a breadth of accessible resource for sector funds like this.

Lead manager, Linden Thomson has nearly two decades of buy-side and sell-side experience as one of the early specialists within the biotechnology sector. Importantly, our managers also have strong, science-focused academic backgrounds that bring credibility to their analysis of the sector. These include MSc Medical Microbiology (Hons), PhD Biochemistry, MPhil Statistical Science; most recently, Cinney Zhang completed an MBA with a thesis titled The Rise of China’s Biotech Sector: What the Future Holds.

Related Articles


Meet The Managers - Q&A with Chris Eccles and Catherine Tennyson

  • by Chris Eccles, Catherine Tennyson
  • 08 April 2024 (5 min read)
Future Trends

Game-changing Alzheimer’s drugs could drive a wave of investment across biotech

  • by Linden Thomson
  • 14 September 2023 (7 min read)

How DNA changed the world of medicine and drives investment opportunities today

  • by Linden Thomson
  • 25 April 2023 (7 min read)

Risk factors

The capital of the Fund is not guaranteed. The Fund is invested in financial markets and uses techniques and instruments which may be subject to sudden and significant variation, which may result in substantial gains or losses.

Single Sector Risk: as this Fund is invested in a single sector, the Fund's value will be more closely aligned with the performance of that sector and it may be subject to greater fluctuations in value than more diversified funds.

Currency Risk: the Fund holds investments denominated in currencies other than the base currency of the Fund. As a result, exchange rate movements may cause the value of investments (and any income received from them) to fall or rise affecting the Fund's value.

Further explanation of the risks associated with an investment in this Fund can be found in the prospectus.


    Not for Retail distribution: This marketing communication is intended exclusively for Professional, Institutional or Wholesale Clients / Investors only, as defined by applicable local laws and regulation. Circulation must be restricted accordingly.

    This marketing communication does not constitute on the part of AXA Investment Managers a solicitation or investment, legal or tax advice. This material does not contain sufficient information to support an investment decision.

    Before making an investment, investors should read the relevant Prospectus and the Key Investor Information Document / scheme documents, which provide full product details including investment charges and risks. The information contained herein is not a substitute for those documents or for professional external advice.
    The products or strategies discussed in this document may not be registered nor available in your jurisdiction. Please check the countries of registration with the asset manager, or on the web site https://www.axa-im.com/en/registration-map, where a fund registration map is available.  In particular units of the funds may not be offered, sold or delivered to U.S. Persons within the meaning of Regulation S of the U.S. Securities Act of 1933. The tax treatment relating to the holding, acquisition or disposal of shares or units in the fund depends on each investor’s tax status or treatment and may be subject to change. Any potential investor is strongly encouraged to seek advice from its own tax advisors.
    For more information on sustainability-related aspects please visit https://www.axa-im.com/what-is-sfdr

    For investors located in the European Union :
    Please note that the management company reserves the right, at any time, to no longer market the product(s) mentioned in this communication in the European Union by filing a notification to its supervision authority, in accordance with European passport rules.

    In the event of dissatisfaction with AXA Investment Managers products or services, you have the right to make a complaint, either with the marketer or directly with the management company (more information on AXA IM complaints policy is available in English: https://www.axa-im.com/important-information/comments-and-complaints ). If you reside in one of the European Union countries, you also have the right to take legal or extra-judicial action at any time. The European online dispute resolution platform allows you to submit a complaint form (available at: https://ec.europa.eu/consumers/odr/main/index.cfm?event=main.home.chooseLanguage) and provides you with information on available means of redress (available at: https://ec.europa.eu/consumers/odr/main/?event=main.adr.show2).
    Summary of investor rights in English is available on AXA IM website https://www.axa-im.com/important-information/summary-investor-rights. Translations into other languages are available on local AXA IM entities’ websites.

    AXA Framlington Biotech Fund is a part of AXA Framlington Range of Authorised Unit Trust Schemes and is managed by AXA Investment Managers UK Limited, part of the AXA IM Group.
    AXA Investment Managers UK Limited, is authorised and regulated by the Financial Conduct Authority in the UK. Registered in England and Wales No: 01431068. Registered Office: 22 Bishopsgate, London EC2N 4BQ. In other jurisdictions, this document is issued by AXA Investment Managers SA’s affiliates in those countries.

    Risk Warning

    The value of investments, and the income from them, can fall as well as rise and investors may not get back the amount originally invested.